How to remedy the lack of research on medicinal cannabis in Europe
A resolution on this subject came into being on Tuesday. The European Commission questioned by MEPs debated how the EU can support research on cannabis-based substances. Standards for non-pharmaceutical medicinal cannabis should also be established to ensure consumer safety.
The draft resolution stresses the need for the European Commission and national authorities to make a clear distinction between medicinal cannabis and cannabis for other uses. It calls on the European Parliament and the Member States to tackle legislative obstacles to scientific research. Adequate funding should be allocated to research and the dissemination of knowledge among health professionals should be encouraged.
In its general context, the European Parliament states that there is substantial evidence of the therapeutic effect of cannabis and cannabinoids. These have an effect on the treatment of chronic pain in adults, nausea and vomiting caused by chemotherapy and improvement of symptoms of muscle spasms in multiple sclerosis.
The World Health Organization has made a formal recommendation that the cannabinoid component of cannabis should not be considered a controlled substance. The legislation on cannabis for medical purposes varies considerably from one Member State to another.